Institute of Hematology & Blood Diseases Hospital in China is conducting a clinical trial to assess the safety and efficacy of using an anti-CD38 antibody, a new type of monoclonal antibody, in the treatment of pediatric ITP in patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy. This treatment works by targeting plasma cells to enhance their survival. Eligible participants include patients who are non-responsive to steroids or are steroid-dependent, or those who have not responded to at least one previous second-line therapy. Participants must be between 12-17 years of age and must have persistent or chronic disease. They must also have a platelet count below 30,000.
China
Actively Recruiting